



## Senzime signs distribution agreement for the Swiss market

**Uppsala, September 18, 2017. Senzime AB (publ) today announced an exclusive distribution agreement with Leuag AG regarding the Swiss market.**

Senzime has entered an exclusive distribution agreement with Leuag AG to enable the commercialization of the TetraGraph anesthesia monitoring system on the Swiss market. Leuag is a leading supplier of global medical brands in the field of patient monitoring, diagnostics and imaging.

Lena Söderström, Senzimes CEO, commented: *"Leuag is a great partner for several reasons. They have a complementary product portfolio, the network and the experience needed to make the TetraGraph a market leader in Switzerland. CE marking is in its final phase and sales will commence directly after this."*

Every year, over 70 million patients undergo surgery and receive muscle relaxant drugs. Research has shown that over 30 percent of patients suffer from postoperative complications if objective neuromuscular monitoring is not used. The easy-to-use TetraGraph anesthesia monitoring system can monitor and objectively determine when the patient is sufficiently recovered to sustain spontaneous breathing.

The system consists of a hand-held unit and non-invasive disposable sensors. The agreement is based on a compensation scheme of "per-unit sold" basis, and is in line with current industry compensation levels without guaranteed sales.



Leuag will be exhibiting the TetraGraph at the [Annual SGAR-SSAR Congress in Interlaken](#), Switzerland November 9-11 together with representatives from Senzime. Read more: [www.leuag.ch](http://www.leuag.ch)

### **For further information, please contact:**

Lena Söderström, CEO of Senzime AB

Tel: +46 708-16 39 12, email: [lena.soderstrom@senzime.com](mailto:lena.soderstrom@senzime.com)

### **TO THE EDITORS**

#### **About Senzime**

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. [www.senzime.com](http://www.senzime.com)

*This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on September 18, 2017.*